These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1149754)

  • 21. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 22. [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
    Eisenlohr JJ; Gehlen W
    Nervenarzt; 1975 Mar; 46(3):128-35. PubMed ID: 805381
    [No Abstract]   [Full Text] [Related]  

  • 23. Senile Parkinsonism and dopa pharmacokinetics.
    Broe GA; Evans MA; Triggs EJ
    Clin Exp Neurol; 1981; 18():174-9. PubMed ID: 6926387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
    Holmsen R
    Tidsskr Nor Laegeforen; 1976 Feb; 96(4):225, 234-6. PubMed ID: 1251394
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 29. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Polygraphic recording of tremor and of hypertonic phenomena. Application to the action of various drugs].
    Truelle JL; Chanelet J; Bastard J; Emile J
    Rev Neurol (Paris); 1975 Jan; 131(1):29-42. PubMed ID: 1101346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW; Muschard F
    Med Welt; 1973 Apr; 24(17):705-7. PubMed ID: 4750934
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
    Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
    Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [L-dopa with extracerebral dope-decarboxylase inhibitor (MK-486) in the treatment of Parkinson's disease. Preliminary evaluation of results].
    Pakszys W; Domzał T
    Neurol Neurochir Pol; 1976; 10(3):345-52. PubMed ID: 951024
    [No Abstract]   [Full Text] [Related]  

  • 36. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor].
    Constantinidis J; de Ajuriaguerra J
    Therapeutique; 1970 Mar; 46(3):263-9. PubMed ID: 5422192
    [No Abstract]   [Full Text] [Related]  

  • 38. Multicenter trial of L-Deprenyl in Parkinson disease.
    Ruggieri S; Denaro A; Meco G; Carta A; Stocchi F; Agnoli A
    Ital J Neurol Sci; 1986 Feb; 7(1):133-7. PubMed ID: 3082793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.